Biofrontera signs exclusive distribution agreement for Belixos® in the Middle East and other Arab countries
(Thomson Reuters ONE) -
Biofrontera AG / Biofrontera signs exclusive distribution agreement for Belixos® in the Middle East and other Arab countries processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Leverkusen, Germany - Biofrontera AG (DSE: B8F) announced that it has signed an
exclusive agreement with Itrom Trading Drug Store in Dubai, a trading arm of
Pharma Consult, Dubai, for the registration, promotion, and distribution of
Biofrontera's Belixos(®) line in the Asian and North African Arab countries.
Belixos(®) is a line of medical cosmetic products. The first product, a cream
especially designed for the care of irritated, dry and itching skin, was
launched in Germany last fall. A cosmetic gel developed to care for sebaceous
and inflamed skin will follow later this year. Both products contain pure herbal
extracts as active ingredients and aim at reducing the requirement for medical
treatment in diseases such as atopic dermatitis, psoriasis, rosacea and acne.
The distribution agreement covers all products of the Belixos(®) line in the
Kingdom of Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman, Bahrain,
Iraq, Yemen, Lebanon, Jordan, Egypt, Sudan, Libya, Algeria, Tunisia and Morocco.
Itrom Trading Drug Store will be responsible, at its own cost, for the
registration of the Belixos® products in these countries, for all promotional
activities, and for the distribution and sales of the product. Biofrontera will
deliver the product at a predetermined price. In addition, Biofrontera will
obtain success-based royalties.
Both companies have agreed on sales targets which Itrom Trading Drug Store
expects to reach in the coming years.
"With Belixos(®) just on the market and our first pharmaceutical product BF-200
ALA approaching the centralized European registration process, Biofrontera is in
a transition phase between a pure research and development company and a
commercial company. At this stage, distribution agreements are relevant aspects,
and we are happy that we found an excellent partner with extensive experience in
the large and rapidly developing cosmetic and pharmaceutical markets of the
Middle East and other Arab Countries," explained Prof. Hermann Lübbert, CEO of
Biofrontera.
About Pharma Consult
Pharma Consult is a sole proprietorship company established in Dubai, UAE in
1998. Pharma Consult is a fully integrated company. With its established
distribution regional network and highly professional marketing team the company
offers general services in terms of registration, marketing, import and
distribution in MENA (Middle East and North Africa) region to international
pharmaceutical companies.
www.pharmaconsult.ae
About Biofrontera AG
Biofrontera AG specializes on the development and distribution of pharmaceutical
or cosmetic products in the area of dermatology. The company is characterized by
a broad, relatively close to the market product portfolio. Biofrontera is listed
in the regulated market of the Düsseldorf stock exchange under the symbol B8F
and the ISIN number DE0006046113.
www.biofrontera.com
This press release contains forward-looking statements based on the currently
held beliefs and assumptions of the management of Biofrontera AG, which are
expressed in good faith and, in their opinion, reasonable. Forward-looking
statements involve known and unknown risks, uncertainties and other factors,
which may cause the assumptions expressed or implied in this press release to be
faulty. Given these risks, uncertainties and other factors, recipients of this
document are cautioned not to place undue reliance on the forward-looking
statements. Biofrontera AG disclaims any obligation to update
For further information please contact:
Anke zur Mühlen
Corporate Communication
+ 49 (0) 214 87632 22
+ 49 (0) 214 87632 90
a.zurmuehlen(at)biofrontera.com
Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen, Germany
[HUG#1395384]
--- End of Message ---
Biofrontera AG
Hemmelrather Weg 201 Leverkusen Germany
WKN: 604611;ISIN: DE0006046113;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München,
Regulierter Markt in Börse Düsseldorf;
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 18.03.2010 - 10:31 Uhr
Sprache: Deutsch
News-ID 1011580
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Leverkusen
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 178 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biofrontera signs exclusive distribution agreement for Belixos® in the Middle East and other Arab countries
"
steht unter der journalistisch-redaktionellen Verantwortung von
Biofrontera AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
